Ponesimod

DRUG7 trials

Sponsors

Actelion, Janssen Pharmaceutica N.V., Belgium, Biogen, Vanda Pharmaceuticals

Conditions

Chronic Graft Versus Host DiseaseHealthyModerate-to-severe Chronic Plaque PsoriasisMultiple Sclerosis

Phase 1

A Study of Ponesimod in Healthy Adult Participants

CompletedNCT05552196

Janssen Pharmaceutica N.V., BelgiumHealthy

Start: 2022-10-18End: 2023-03-29Updated: 2025-04-27

Phase 2

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

TerminatedNCT02461134

ActelionChronic Graft Versus Host Disease

Start: 2016-09-29End: 2017-03-03Updated: 2025-02-04

Phase 3

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

CompletedNCT02425644

ActelionMultiple Sclerosis

Start: 2015-06-04End: 2019-05-16Updated: 2025-03-30

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

TerminatedNCT02907177

ActelionMultiple Sclerosis

Start: 2017-03-30End: 2020-03-26Updated: 2021-05-18

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

CompletedNCT03232073

ActelionMultiple Sclerosis

Start: 2017-07-05End: 2024-01-16Updated: 2025-06-22

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Not yet recruitingNCT07362017

Vanda PharmaceuticalsModerate-to-severe Chronic Plaque Psoriasis

Start: 2026-01-01End: 2028-12-01Target: 300Updated: 2026-01-23

Unknown Phase

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

RecruitingNCT05688436

BiogenMultiple Sclerosis

Start: 2021-09-24End: 2031-01-17Target: 1178Updated: 2025-10-17

Related Papers

Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.

2025-07-13

Meaningful Change Thresholds and Fatigue Severity Points on Patient-Reported Outcomes by the Fatigue Symptoms and Impacts Questionnaire in Patients With Relapsing Multiple Sclerosis.

2024-02-232 citations

Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study

Journal of Women s Health2024-02-011 citations

Patients treated with ponesimod demonstrate reductions in serum neurofilament light chain levels

2023-11-01

Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.

2023-05-084 citations

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

JAMA Neurology2021-03-29203 citations

Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority

Frontiers in Neurology2019-07-165 citations